NYSE:MD - MEDNAX Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $26.37 +0.80 (+3.13 %) (As of 04/24/2019 08:05 AM ET)Previous Close$25.57Today's Range$25.5150 - $26.6652-Week Range$25.47 - $53.17Volume1.19 million shsAverage Volume1.20 million shsMarket Capitalization$2.32 billionP/E Ratio7.51Dividend YieldN/ABeta0.58 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and their unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, and pediatric surgeons, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of December 31, 2018, it had a network of approximately 4,210 affiliated physicians. The company was founded in 1979 and is based in Sunrise, Florida. Receive MD News and Ratings via Email Sign-up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Hospitals Sub-IndustryHealth Care Services SectorMedical Current SymbolNYSE:MD Previous SymbolNYSE:PDX CUSIP58502B10 CIK893949 Webwww.mednax.com Phone954-384-0175Debt Debt-to-Equity Ratio0.64 Current Ratio1.31 Quick Ratio1.31Price-To-Earnings Trailing P/E Ratio7.51 Forward P/E Ratio7.69 P/E Growth0.95 Sales & Book Value Annual Sales$3.65 billion Price / Sales0.64 Cash Flow$4.9661 per share Price / Cash Flow5.31 Book Value$34.53 per share Price / Book0.76Profitability EPS (Most Recent Fiscal Year)$3.51 Net Income$268.62 million Net Margins7.37% Return on Equity10.35% Return on Assets5.47%Miscellaneous Employees7,625 Outstanding Shares87,869,000Market Cap$2.32 billion Next Earnings Date5/2/2019 (Confirmed) OptionableOptionable MEDNAX (NYSE:MD) Frequently Asked Questions What is MEDNAX's stock symbol? MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD." How were MEDNAX's earnings last quarter? MEDNAX Inc (NYSE:MD) released its earnings results on Thursday, February, 7th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.83 by $0.09. The company had revenue of $932.70 million for the quarter, compared to the consensus estimate of $910.08 million. MEDNAX had a net margin of 7.37% and a return on equity of 10.35%. MEDNAX's quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.87 EPS. View MEDNAX's Earnings History. When is MEDNAX's next earnings date? MEDNAX is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for MEDNAX. How can I listen to MEDNAX's earnings call? MEDNAX will be holding an earnings conference call on Thursday, May 2nd at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link. What guidance has MEDNAX issued on next quarter's earnings? MEDNAX updated its first quarter earnings guidance on Thursday, February, 7th. The company provided earnings per share (EPS) guidance of $0.67-0.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.86. MEDNAX also updated its Q1 2019 guidance to $0.67-0.75 EPS. What price target have analysts set for MD? 11 brokers have issued twelve-month price targets for MEDNAX's stock. Their predictions range from $31.00 to $50.00. On average, they anticipate MEDNAX's stock price to reach $40.4436 in the next twelve months. This suggests a possible upside of 53.4% from the stock's current price. View Analyst Price Targets for MEDNAX. What is the consensus analysts' recommendation for MEDNAX? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX. Has MEDNAX been receiving favorable news coverage? Media coverage about MD stock has trended somewhat negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. MEDNAX earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the near term. Who are some of MEDNAX's key competitors? Some companies that are related to MEDNAX include Encompass Health (EHC), Healthscope (HSO), Select Medical (SEM), Primary Health Care (PRY), Magellan Health (MGLN), Medical Facilities (DR), Capitol Health (CAJ), Animalcare Group (ANCR), SunLink Health Systems (SSY), Spine Injury Solutions (SPIN) and THC Biomed Intl (THC). What other stocks do shareholders of MEDNAX own? Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include Micron Technology (MU), Dominion Energy (D), Pfizer (PFE), Gilead Sciences (GILD), NVIDIA (NVDA), General Electric (GE), Cisco Systems (CSCO), QUALCOMM (QCOM), AbbVie (ABBV) and Boeing (BA). Who are MEDNAX's key executives? MEDNAX's management team includes the folowing people: Dr. Roger J. Medel, Co-Founder, CEO & Director (Age 72)Mr. Joseph M. Calabro, Pres & COO (Age 58)Mr. Dominic J. Andreano, Sr. VP, Gen. Counsel & Sec. (Age 50)Mr. David A. Clark, Pres of Mednax National Medical Group Division (Age 52)Mr. Stephen D. Farber, Exec. VP & CFO (Age 49) Who are MEDNAX's major shareholders? MEDNAX's stock is owned by many different of institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.13%), Triad Investment Management (0.08%), Sciencast Management LP (0.04%), Tibra Equities Europe Ltd (0.03%), 6 Meridian (0.02%) and First Hawaiian Bank (0.01%). Company insiders that own MEDNAX stock include Cesar L Alvarez, David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Manuel Kadre, Md Pascal J Goldschmidt and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX. Which institutional investors are selling MEDNAX stock? MD stock was sold by a variety of institutional investors in the last quarter, including First Hawaiian Bank and Retirement Systems of Alabama. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt and Vivian Lopez-Blanco. View Insider Buying and Selling for MEDNAX. Which institutional investors are buying MEDNAX stock? MD stock was acquired by a variety of institutional investors in the last quarter, including Sciencast Management LP, Tibra Equities Europe Ltd, Virtu Financial LLC, 6 Meridian, Investors Research Corp, Tompkins Financial Corp, First Bank & Trust and Triad Investment Management. View Insider Buying and Selling for MEDNAX. How do I buy shares of MEDNAX? Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is MEDNAX's stock price today? One share of MD stock can currently be purchased for approximately $26.37. How big of a company is MEDNAX? MEDNAX has a market capitalization of $2.32 billion and generates $3.65 billion in revenue each year. The company earns $268.62 million in net income (profit) each year or $3.51 on an earnings per share basis. MEDNAX employs 7,625 workers across the globe. What is MEDNAX's official website? The official website for MEDNAX is http://www.mednax.com. How can I contact MEDNAX? MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected] MarketBeat Community Rating for MEDNAX (NYSE MD)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 432 (Vote Outperform)Underperform Votes: 460 (Vote Underperform)Total Votes: 892MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: Are 12b-1 Fees Affecting Your Mutual Fund Performance?